Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Aarhus
With
Nordic Lymphoma Group
Age
18–67
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Previously untreated patients with newly diagnosed peripheral T-cell lymphoma of all stages. However, patients with nodal stage IA non-bulky disease (\<10cm) can be treated individually at the discretion of the responsible physician.
Following histologic subtypes (WHO classification) are eligible for inclusion in the study:
Patients with severe cardiac (i.e. severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45%), pulmonary, neurologic, psychiatric, renal, hepatic or metabolic disease.
Pregnancy. N.B: Women of childbearing potential should be strongly advised to apply appropriate contraceptive precautions during the entire treatment period.
Patients with concomitant malignancies except for non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
Patients with seropositivity for the human immunodeficiency virus.
Patients with other active and therapeutically uncontrolled infection.
Psychological, familial, social or other condition/-s potentially hampering compliance and follow-up.
Clareo Health | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT
